Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Top Page
Karyopharm Therapeutics
(NASDAQ:KPTI)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.50
▲(0.36% Upside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by weak financial performance (persistent losses, negative equity, and ongoing cash burn). Technicals also reflect a bearish trend despite oversold readings. Offsetting factors include extended liquidity from financings/credit relief and meaningful clinical catalysts, but guidance and dependency on binary trial outcomes keep overall risk elevated.
Positive Factors
Very high product gross margins
Sustained gross margins near 96–98% indicate XPOVIO has highly efficient product economics. That margin profile provides substantial operating leverage as sales scale, meaning moderate revenue growth could translate into material incremental contribution toward covering fixed R&D/SG&A and improving path to profitability.
Negative Factors
Consistently negative shareholders' equity
Multi-year negative shareholders’ equity reflects cumulative losses and capital structure strain. This weak capitalization limits financial flexibility, increases reliance on external financing, and can constrain strategic options or borrowing capacity during downturns, raising long-term solvency and dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Very high product gross margins
Sustained gross margins near 96–98% indicate XPOVIO has highly efficient product economics. That margin profile provides substantial operating leverage as sales scale, meaning moderate revenue growth could translate into material incremental contribution toward covering fixed R&D/SG&A and improving path to profitability.
Read all positive factors
Karyopharm Therapeutics (KPTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$100.52M
Dividend YieldN/A
Average Volume (3M)228.24K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue Growth-3.98%
EPS Growth-29.94%
CountryUS
Employees279
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.71
Shares Outstanding18,343,967
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market Cap2.19
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit1.57
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
$16.40Price Target Upside199.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.77
Revenue Forecast (FY)$138.92M
Karyopharm Therapeutics Business Overview & Revenue Model
Company Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commerciali...
How the Company Makes Money
Karyopharm makes money primarily through net product revenue from sales of its marketed drug XPOVIO (selinexor). This revenue stream reflects gross sales to customers (e.g., specialty distributors and healthcare channels) net of typical pharmaceut...
Karyopharm Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Type
Separates sales into product revenue, collaboration and licensing income, milestones, royalties, and other sources to show what actually drives cash flow. Reveals whether the company’s income is coming from repeatable drug sales (commercial traction for XPOVIO) or from irregular, one-time partner payments—key for judging predictability, growth sustainability, and runway risk.
Separates sales into product revenue, collaboration and licensing income, milestones, royalties, and other sources to show what actually drives cash flow. Reveals whether the company’s income is coming from repeatable drug sales (commercial traction for XPOVIO) or from irregular, one-time partner payments—key for judging predictability, growth sustainability, and runway risk.
Data provided by:
The Fly
The FlyKaryopharm Therapeutics Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but measured outlook: strong near‑term clinical catalysts (SENTRY in March and EXPORT EC042 mid‑2026), encouraging early efficacy and tolerability data, modest product revenue growth and demonstrated cost discipline. Offsetting these positives are a constrained cash runway (into Q2 2026), large GAAP losses driven by debt‑related and noncash items, elevated interest expense, and dependence on binary Phase III readouts to drive future value. Overall, the balance of significant upside potential from pending pivotal data against material near‑term financial constraints yields a neutral stance.Positive Updates
Upcoming Pivotal Phase III Readouts
Top-line data for Phase III SENTRY (myelofibrosis) expected in March 2026 and Phase III EXPORT EC042 (endometrial cancer) expected mid-2026 — both positioned as potential practice‑changing events and primary near‑term value drivers for the company.
Negative Updates
Limited Cash Runway and Near‑Term Liquidity Need
Cash, cash equivalents, restricted cash and investments ended at $64.1M (down from $109.1M at 12/31/2024). Management states existing liquidity supports operations into the second quarter of 2026, aligning runway tightly with upcoming Phase III readouts and necessitating financing or strategic options thereafter.
Read all updates
Q4-2025 Updates
Positive
Negative
Upcoming Pivotal Phase III Readouts
Top-line data for Phase III SENTRY (myelofibrosis) expected in March 2026 and Phase III EXPORT EC042 (endometrial cancer) expected mid-2026 — both positioned as potential practice‑changing events and primary near‑term value drivers for the company.
Read all positive updates
Company Guidance
Karyopharm guided 2026 total revenue of $130–$150 million, including U.S. XPOVIO net product revenue of $115–$130 million (with the balance from license/royalty/milestone revenue from partners such as Menarini and Antengene), and expects combined R&D and SG&A of $230–$245 million; management said existing liquidity plus projected XPOVIO and partner revenues fund operations into the second quarter of 2026. For context, 4Q25 total revenue was $34.1M (+11.8% vs. 4Q24) and FY25 total revenue was $146.1M; 4Q25 U.S. XPOVIO net product revenue was $32.1M (+9.6%) and FY25 was $114.9M (+1.9%); gross-to-net was 26.9% in 4Q and 31.2% for the year; license/other revenue was $2.0M in 4Q and $31.2M for FY (including $15.0M R&D reimbursement from Menarini); 4Q R&D was $27.7M (‑17% YoY) and FY R&D $125.6M (‑12%); 4Q SG&A $22.8M (‑16%) and FY SG&A $105.2M (‑9%); interest expense was $12.6M in 4Q and $45.8M for the year; GAAP net loss was $102.2M (‑$5.71/sh) in 4Q25 and $196.0M (‑$17.93/sh) for FY25; year‑end cash, cash equivalents, restricted cash and investments totaled $64.1M (down from $109.1M at 12/31/24).Karyopharm Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 146.07M | 145.24M | 146.03M | 157.07M | 209.82M |
| Gross Profit | 140.12M | 139.23M | 141.09M | 151.86M | 206.42M |
| EBITDA | -90.41M | -38.60M | -118.42M | -139.31M | -96.98M |
| Net Income | -196.04M | -76.42M | -143.10M | -165.29M | -124.09M |
Balance Sheet | |||||
| Total Assets | 108.42M | 164.42M | 240.44M | 358.17M | 305.31M |
| Cash, Cash Equivalents and Short-Term Investments | 63.74M | 108.71M | 191.44M | 277.97M | 228.62M |
| Total Debt | 233.61M | 194.52M | 177.02M | 179.07M | 180.58M |
| Total Liabilities | 401.34M | 350.44M | 376.64M | 374.83M | 384.98M |
| Stockholders Equity | -292.93M | -186.02M | -136.21M | -16.66M | -79.67M |
Cash Flow | |||||
| Free Cash Flow | -75.37M | -127.63M | -92.72M | -149.67M | -112.83M |
| Operating Cash Flow | -75.37M | -127.49M | -92.72M | -149.55M | -107.12M |
| Investing Cash Flow | 43.38M | 95.47M | 7.94M | -104.26M | 141.84M |
| Financing Cash Flow | 30.05M | 41.65M | 1.12M | 193.74M | 73.65M |
Karyopharm Therapeutics Technical Analysis
Negative
5.48
Price Trends
7.68
Negative
7.06
Negative
6.24
Negative
Market Momentum
-0.71
Positive
29.93
Positive
9.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Negative. The current price of 5.48 is below the 20-day moving average (MA) of 7.79, below the 50-day MA of 7.68, and below the 200-day MA of 6.24, indicating a bearish trend. The MACD of -0.71 indicates Positive momentum. The RSI at 29.93 is Positive, neither overbought nor oversold. The STOCH value of 9.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPTI.
Karyopharm Therapeutics Risk Analysis
Karyopharm Therapeutics disclosed 68 risk factors in its most recent earnings report. Karyopharm Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Karyopharm Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $12.53M | -2.82 | -125.98% | ― | ― | 1.18% | |
46 Neutral | $363.04M | -1.12 | -4.88% | ― | 4121.12% | 83.30% | |
45 Neutral | $100.52M | -0.41 | 77.87% | ― | -3.98% | -29.94% | |
45 Neutral | $32.13M | -2.43 | -151.67% | ― | 11.11% | 20.65% | |
43 Neutral | $30.68M | -0.28 | 71.83% | ― | -66.96% | 71.83% | |
42 Neutral | $17.71M | -1.04 | -2986.76% | ― | ― | -55.95% |
* Healthcare Sector Average
KPTI
Karyopharm Therapeutics
5.48
1.74
46.52%
ATNM
Actinium Pharmaceuticals
1.03
-0.58
-36.02%
BTAI
Bioxcel Therapeutics
1.26
-0.77
-37.93%
LTRN
Lantern Pharma
1.12
-2.42
-68.36%
IPSC
Century Therapeutics
2.02
1.54
324.37%
MDCX
Medicus Pharma Ltd
0.45
-3.27
-87.90%
Karyopharm Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Karyopharm Strengthens Liquidity With New Equity Financing
Positive
Mar 27, 2026
On March 24, 2026, Karyopharm Therapeutics Inc. entered into a securities purchase agreement with RA Capital Management for a private placement of common stock, pre-funded warrants, and accompanying warrants, which closed on March 26, 2026 and gen...
Business Operations and StrategyPrivate Placements and Financing
Karyopharm Announces Financing and Positive SENTRY Trial Results
Positive
Mar 24, 2026
On March 24, 2026, Karyopharm announced a $30 million private placement with RA Capital Management, issuing common stock, pre-funded warrants and additional common stock warrants, with potential extra proceeds of about $44 million upon full warran...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Karyopharm Amends Credit Agreement to Extend Liquidity Runway
Positive
Mar 3, 2026
On February 27, 2026, Karyopharm Therapeutics Inc. amended its existing Credit and Guaranty Agreement to reduce near-term cash outflows and extend its liquidity runway beyond the second quarter of 2026, aligning with the anticipated mid-2026 reado...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Karyopharm Shareholders Approve Major Authorized Share Increase
Positive
Feb 19, 2026
On February 18, 2026, Karyopharm Therapeutics Inc. stockholders approved an amendment to the company’s Restated Certificate of Incorporation to increase total authorized capital stock from 58,333,333 to 111,000,000 shares and authorized comm...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Karyopharm Issues Preliminary 2025 Financial Results and Outlook
Positive
Jan 12, 2026
On January 12, 2026, Karyopharm reported preliminary unaudited financial results indicating it expects approximately $33 million in total revenue for the fourth quarter of 2025 and about $145 million for full-year 2025, including $32 million and $...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.